{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T15:53:03Z","timestamp":1759333983604,"version":"build-2065373602"},"reference-count":51,"publisher":"BMJ","issue":"9","license":[{"start":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T00:00:00Z","timestamp":1759104000000},"content-version":"unspecified","delay-in-days":28,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"crossref","award":["AWD-014048"],"award-info":[{"award-number":["AWD-014048"]}],"id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"accepted":{"date-parts":[[2025,8,21]]},"published-print":{"date-parts":[[2025,9]]},"abstract":"<jats:sec>\n                  <jats:title>Introduction<\/jats:title>\n                  <jats:p>The Quadrivalent human papillomavirus (HPV) Vaccine Evaluation Study with Addition of the Nonavalent Vaccine Study (QUEST-ADVANCE) aims to provide insight into the long-term immunogenicity and effectiveness of one, two and three HPV vaccine doses. Here, we describe the protocol for QUEST-ADVANCE.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods and analysis<\/jats:title>\n                  <jats:p>QUEST-ADVANCE is an observational cohort study including males and females who are unvaccinated or vaccinated with the quadrivalent or nonavalent HPV vaccine in British Columbia, Canada. Female participants who are unvaccinated or vaccinated with 1\u20133 doses of the quadrivalent or nonavalent HPV vaccine at 9\u201314 years of age will be recruited approximately 5 or 12 years postvaccination eligibility. Male participants who are unvaccinated or vaccinated with 1 or 2 doses of the nonavalent HPV vaccine at 9\u201314 years of age will be recruited at approximately 5 years postvaccination eligibility. The study involves a maximum of four visits over a period of 4\u20135 years for female participants, and two visits over a 12-month period for male participants. At each visit, self-collected swabs (cervico-vaginal or penile) and questionnaire data will be collected. In each study group, a subset of participants will be invited to participate in a substudy evaluating the long-term humoral immunogenicity of the HPV vaccine. Additional blood samples will be collected from participants who are part of the immunogenicity substudy. The total required sample size is 7180 individuals. The primary objectives are (1) to examine vaccine effectiveness in males and females against prevalent genital HPV infections for one, two and three doses of the HPV vaccine compared with unvaccinated participants and (2) to evaluate if there is non-inferior immunogenicity as indicated by type-specific antibody response of one dose of the HPV vaccine in 20\u201327-year-old females vaccinated at 9\u201314 years of age compared with historical data of three doses of the HPV vaccine females vaccinated at 16\u201326 years of age up to 12 years postvaccination.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Ethics and dissemination<\/jats:title>\n                  <jats:p>QUEST-ADVANCE was approved by the Research Ethics Board of the University of British Columbia\/Children\u2019s and Women\u2019s Health Centre of British Columbia (H20-02111). Individual electronic informed consent or assent will be obtained from each participant before any study-specific procedures are undertaken. Results will be published in an international peer-reviewed journal and on the study website.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1136\/bmjopen-2025-100560","type":"journal-article","created":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T09:15:52Z","timestamp":1759223752000},"page":"e100560","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":0,"title":["Quadrivalent HPV Vaccine Evaluation Study with Addition of the Nonavalent Vaccine (QUEST-ADVANCE): protocol of an observational cohort study"],"prefix":"10.1136","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8762-4822","authenticated-orcid":false,"given":"Marit","family":"Middeldorp","sequence":"first","affiliation":[{"name":"BC Children\u2019s Hospital Research Institute, Vaccine Evaluation Center, Vancouver, British Columbia, Canada"},{"name":"Women\u2019s Health Research Institute, BC Women\u2019s Hospital and Health Service, Vancouver, British Columbia, Canada"},{"name":"Centre for Infectious Disease Control, National Institute for Public Health and the Environment, Bilthoven, The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robine","family":"Donken","sequence":"additional","affiliation":[{"name":"BC Children\u2019s Hospital Research Institute, Vaccine Evaluation Center, Vancouver, British Columbia, Canada"},{"name":"Women\u2019s Health Research Institute, BC Women\u2019s Hospital and Health Service, Vancouver, British Columbia, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aarthi","family":"Nirmal","sequence":"additional","affiliation":[{"name":"BC Children\u2019s Hospital Research Institute, Vaccine Evaluation Center, Vancouver, British Columbia, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brenda","family":"Smith","sequence":"additional","affiliation":[{"name":"Provincial Laboratory Medicine Services, BC Cancer Agency, Vancouver, British Columbia, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ana","family":"Citlali Marquez","sequence":"additional","affiliation":[{"name":"Communicable Diseases and Immunization Services, BC Centre for Disease Control, Vancouver, British Columbia, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2118-4174","authenticated-orcid":false,"given":"Julie A","family":"Bettinger","sequence":"additional","affiliation":[{"name":"BC Children\u2019s Hospital Research Institute, Vaccine Evaluation Center, Vancouver, British Columbia, Canada"},{"name":"Department of Pediatrics, The University of British Columbia, Vancouver, British Columbia, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marc","family":"Brisson","sequence":"additional","affiliation":[{"name":"Department of Social and Preventive Medicine, Laval University, Qu\u00e9bec City, Qu\u00e9bec, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2822-2169","authenticated-orcid":false,"given":"Ann N","family":"Burchell","sequence":"additional","affiliation":[{"name":"Department of Family and Community Medicine and MAP Centre for Urban Health Solutions, Li Ka Shing Knowledge Institute, St. Michael\u2019s Hospital, Unity Health Toronto, Toronto, Ontario, Canada"},{"name":"Temerty Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1444-3489","authenticated-orcid":false,"given":"Simon R","family":"Dobson","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, The University of British Columbia, Vancouver, British Columbia, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Meena","family":"Dawar","sequence":"additional","affiliation":[{"name":"Vancouver Coastal Health Authority, Vancouver, British Columbia, Canada"},{"name":"Cancer Control Research, BC Cancer, Vancouver, British Columbia, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4409-8084","authenticated-orcid":false,"given":"Eduardo L","family":"Franco","sequence":"additional","affiliation":[{"name":"Division of Cancer Epidemiology, McGill University, Montreal, Quebec, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Troy","family":"Grennan","sequence":"additional","affiliation":[{"name":"Communicable Diseases and Immunization Services, BC Centre for Disease Control, Vancouver, British Columbia, Canada"},{"name":"Faculty of Medicine, The University of British Columbia, Vancouver, British Columbia, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mel","family":"Krajden","sequence":"additional","affiliation":[{"name":"Centre for Advancing Health Outcomes, The University of British Columbia, Vancouver, British Columbia, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marie-H\u00e9l\u00e8ne","family":"Mayrand","sequence":"additional","affiliation":[{"name":"Departments of Obstetrics and Gynecology, Universit\u00e9 de Montr\u00e9al and Research Center of the Centre hospitalier de l\u2019Universit\u00e9 de Montr\u00e9al, Montreal, Quebec, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shelly","family":"McNeil","sequence":"additional","affiliation":[{"name":"Infectious Diseases, Dalhousie University, Halifax, Nova Scotia, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Monika","family":"Naus","sequence":"additional","affiliation":[{"name":"Communicable Diseases and Immunization Services, BC Centre for Disease Control, Vancouver, British Columbia, Canada"},{"name":"Faculty of Medicine, The University of British Columbia, Vancouver, British Columbia, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chantal","family":"Sauvageau","sequence":"additional","affiliation":[{"name":"Department of Social and Preventive Medicine, Laval University, Qu\u00e9bec City, Qu\u00e9bec, Canada"},{"name":"Centre de recherche du Centre Hospitalier Universitaire de Qu\u00e9bec\u2013Universite Laval, Qu\u00e9bec City, Qu\u00e9bec, Canada"},{"name":"Biological and Occupational Risks, Institut national de sante publique du Qu\u00e9bec, Qu\u00e9bec City, Qu\u00e9bec, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joel","family":"Singer","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, The University of British Columbia, Vancouver, British Columbia, Canada"},{"name":"Centre for Advancing Health Outcomes, The University of British Columbia, Vancouver, British Columbia, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9463-1713","authenticated-orcid":false,"given":"Laurie W","family":"Smith","sequence":"additional","affiliation":[{"name":"Women\u2019s Health Research Institute, BC Women\u2019s Hospital and Health Service, Vancouver, British Columbia, Canada"},{"name":"Cancer Control Research, BC Cancer Agency, Vancouver, British Columbia, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5783-4493","authenticated-orcid":false,"given":"Gina S","family":"Ogilvie","sequence":"additional","affiliation":[{"name":"Women\u2019s Health Research Institute, BC Women\u2019s Hospital and Health Service, Vancouver, British Columbia, Canada"},{"name":"Communicable Diseases and Immunization Services, BC Centre for Disease Control, Vancouver, British Columbia, Canada"},{"name":"Faculty of Medicine, The University of British Columbia, Vancouver, British Columbia, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manish","family":"Sadarangani","sequence":"additional","affiliation":[{"name":"BC Children\u2019s Hospital Research Institute, Vaccine Evaluation Center, Vancouver, British Columbia, Canada"},{"name":"Department of Pediatrics, The University of British Columbia, Vancouver, British Columbia, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2025,9,30]]},"reference":[{"key":"2025093002151310000_15.9.e100560.1","doi-asserted-by":"publisher","DOI":"10.1097\/OLQ.0000000000000193"},{"key":"2025093002151310000_15.9.e100560.2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(06)68439-0"},{"key":"2025093002151310000_15.9.e100560.3","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(05)70101-7"},{"key":"2025093002151310000_15.9.e100560.4","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1405044"},{"key":"2025093002151310000_15.9.e100560.5","unstructured":"World Health Organization . Accelerating the elimination of cervical cancer as a global public health problem. World Health Organization, Regional Office for South-East Asia; 2019."},{"key":"2025093002151310000_15.9.e100560.6","doi-asserted-by":"publisher","DOI":"10.1016\/s2468-2667(18)30183-x"},{"key":"2025093002151310000_15.9.e100560.7","doi-asserted-by":"crossref","first-page":"e213","DOI":"10.1016\/S2468-2667(20)30006-2","article-title":"Projected time to elimination of cervical cancer in the USA: a comparative modelling study","volume":"5","author":"Burger","year":"2020","journal-title":"Lancet Public Health"},{"key":"2025093002151310000_15.9.e100560.8","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1016\/S0140-6736(20)30068-4","article-title":"Impact of HPV vaccination and cervical screening on cervical cancer elimination: a comparative modelling analysis in 78 low-income and lower-middle-income countries","volume":"395","author":"Brisson","year":"2020","journal-title":"The Lancet"},{"key":"2025093002151310000_15.9.e100560.9","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.29508"},{"key":"2025093002151310000_15.9.e100560.10","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiy067"},{"key":"2025093002151310000_15.9.e100560.11","doi-asserted-by":"crossref","first-page":"4800","DOI":"10.1016\/j.vaccine.2018.02.004","article-title":"Early use of the HPV 2-dose vaccination schedule: Leveraging evidence to support policy for accelerated impact","volume":"36","author":"Gilca","year":"2018","journal-title":"Vaccine (Auckl)"},{"key":"2025093002151310000_15.9.e100560.12","unstructured":"BC Centre for Disease Control . Immunization coverage in grade 6 students, 2011-2020. Vancouver, 2022."},{"key":"2025093002151310000_15.9.e100560.13","unstructured":"BC Centre for Disease Control . Immunization coverage in grade 9 students, 2013-2023. Vancouver, 2024."},{"key":"2025093002151310000_15.9.e100560.14","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1093\/jnci\/djaa010","article-title":"Durability of Cross-Protection by Different Schedules of the Bivalent HPV Vaccine: The CVT Trial","volume":"112","author":"Tsang","year":"2020","journal-title":"JNCI"},{"key":"2025093002151310000_15.9.e100560.15","doi-asserted-by":"crossref","first-page":"4774","DOI":"10.1016\/j.vaccine.2017.12.078","article-title":"Evidence for single-dose protection by the bivalent HPV vaccine-Review of the Costa Rica HPV vaccine trial and future research studies","volume":"36","author":"Kreimer","year":"2018","journal-title":"Vaccine (Auckl)"},{"key":"2025093002151310000_15.9.e100560.16","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djaa011"},{"key":"2025093002151310000_15.9.e100560.17","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1093\/cid\/ciz239","article-title":"Dose-related Effectiveness of Quadrivalent Human Papillomavirus Vaccine Against Cervical Intraepithelial Neoplasia: A Danish Nationwide Cohort Study","volume":"70","author":"Verdoodt","year":"2020","journal-title":"Clin Infect Dis"},{"key":"2025093002151310000_15.9.e100560.18","doi-asserted-by":"publisher","DOI":"10.1016\/j.pvr.2019.100177"},{"key":"2025093002151310000_15.9.e100560.19","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.32700"},{"key":"2025093002151310000_15.9.e100560.20","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/j.vaccine.2022.11.044","article-title":"Evaluation of immune response to single dose of quadrivalent HPV vaccine at 10-year post-vaccination","volume":"41","author":"Joshi","year":"2023","journal-title":"Vaccine (Auckl)"},{"key":"2025093002151310000_15.9.e100560.21","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(21)00453-8"},{"key":"2025093002151310000_15.9.e100560.22","doi-asserted-by":"crossref","first-page":"4783","DOI":"10.1016\/j.vaccine.2018.02.087","article-title":"Can a single dose of human papillomavirus (HPV) vaccine prevent cervical cancer? Early findings from an Indian study","volume":"36","author":"Sankaranarayanan","year":"2018","journal-title":"Vaccine (Auckl)"},{"key":"2025093002151310000_15.9.e100560.23","unstructured":"Romero B , Herrero R , Porras C , et al . Durability of HPV-16\/18 antibodies 16 years after a single dose of the bivalent vaccine: the costa rica HPV vaccine trial. 35th International Papillomavirus Conference; 2023 Apr 17; Washington DC, USA."},{"key":"2025093002151310000_15.9.e100560.24","unstructured":"Donken R , Sadarangani M , Cook D , et al . After a two-dose schedule in girls no prevalent HPV16\/18 infections were found; an interim analysis from the quadrivalent HPV vaccine evaluation study. 2018."},{"key":"2025093002151310000_15.9.e100560.25","unstructured":"Ogilvie G , McNeil S , Sauvageau C , et al . Quadrivalent vaccine evaluation study (QUEST): longitudinal study evaluating effectiveness of reduced dosing of the quadrivalent HPV vaccine (Q-HPV). Presented at the Canadian Immunization Research Network (CIRN) AGM; 2016"},{"key":"2025093002151310000_15.9.e100560.26","unstructured":"Public Health Agency of Canada . Summary of NACI statement of July 24, 2024: updated recommendations on human papillomavirus vaccines. 2024."},{"key":"2025093002151310000_15.9.e100560.27","first-page":"645","article-title":"Human papillomavirus vaccines: WHO position paper, December 2022","volume":"97","year":"2022","journal-title":"Weekly Epidemiological Record"},{"key":"2025093002151310000_15.9.e100560.28","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1093\/infdis\/jiz555","article-title":"Human Papillomavirus Vaccine Effectiveness Against HPV Infection: Evaluation of One, Two, and Three Doses","volume":"221","author":"Markowitz","year":"2020","journal-title":"J Infect Dis"},{"key":"2025093002151310000_15.9.e100560.29","unstructured":"IARC HPV Working Group . Primary end-points for prophylactic HPV vaccine trials. 2014."},{"key":"2025093002151310000_15.9.e100560.30","unstructured":"Statistics Canada . Table 17-10-0005-01 population estimates on July 1st, by age and sex. 2022. Available: https:\/\/doi.org\/10.25318\/1710000501-eng [Accessed 22 Dec 2023]."},{"key":"2025093002151310000_15.9.e100560.31","unstructured":"Statistics Canada . Table 98-10-0385-01 high school completion by census year: Canada, provinces and territories, census metropolitan areas and census agglomerations. 2023. Available: https:\/\/doi.org\/10.25318\/9810038501-eng [Accessed 29 Dec 2023]."},{"key":"2025093002151310000_15.9.e100560.32","unstructured":"Provincial Health Services Authority (PHSA) . Provincial public health information systems. 2024. Available: http:\/\/www.phsa.ca\/health-professionals\/clinical-tools-applications\/provincial-public-health-information-system [Accessed 06 Sep 2024]."},{"key":"2025093002151310000_15.9.e100560.33","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbi.2008.08.010"},{"key":"2025093002151310000_15.9.e100560.34","doi-asserted-by":"publisher","DOI":"10.1136\/sti.2008.033068"},{"key":"2025093002151310000_15.9.e100560.35","doi-asserted-by":"crossref","first-page":"2718","DOI":"10.1002\/ijc.31989","article-title":"Assessment of herd effects among women and heterosexual men after girls-only HPV16\/18 vaccination in the Netherlands: A repeated cross-sectional study","volume":"144","author":"Woestenberg","year":"2019","journal-title":"Int J Cancer"},{"key":"2025093002151310000_15.9.e100560.36","unstructured":"Sauvageau C , Mayrand HM , Ouakki M , et al . Protection against hpv16\/18 persistent infections for up to 13 years after vaccination of 9-11-year-old girsl with 2-dose or 3-dose extended-schedule of quadrivalent vaccine. Presented at the International papillomavirus conference (IPVC), Washington; 2023"},{"key":"2025093002151310000_15.9.e100560.37","unstructured":"HealthLinkBC . Human papillomavirus (HPV) vaccines. 2024. Available: https:\/\/www.healthlinkbc.ca\/healthlinkbc-files\/human-papillomavirus-hpv-vaccines [Accessed 16 Nov 2023]."},{"key":"2025093002151310000_15.9.e100560.38","unstructured":"BCcancer, Provincial Health Services Authority . Cervix screening. 2024. Available: http:\/\/www.bccancer.bc.ca\/screening [Accessed 18 May 2024]."},{"key":"2025093002151310000_15.9.e100560.39","unstructured":"BC Cancer . BC cancer cervix screening program program overview. 2023. Available: http:\/\/www.bccancer.bc.ca\/screening\/Documents\/Cervix-Program-Overview.pdf [Accessed 06 Sep 2024]."},{"key":"2025093002151310000_15.9.e100560.40","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1093\/cid\/ciz887","article-title":"Immunogenicity of 2 and 3 Doses of the Quadrivalent Human Papillomavirus Vaccine up to 120 Months Postvaccination: Follow-up of a Randomized Clinical Trial","volume":"71","author":"Donken","year":"2020","journal-title":"Clin Infect Dis"},{"key":"2025093002151310000_15.9.e100560.41","unstructured":"Donken R , Sadarangani M , Cook D , et al . No prevalent HPV16\/18 infections among girls vaccinated with a two-dose schedule; an interim analysis from the Quadrivalent HPV vaccine evaluation study. ESPID, 2018."},{"key":"2025093002151310000_15.9.e100560.42","unstructured":"IARC HPV Working Group . Primary end-points for prophylactic HPV vaccine trials, 2014. International Agency for Research on Cancer; 2019."},{"key":"2025093002151310000_15.9.e100560.43","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2013.1625"},{"key":"2025093002151310000_15.9.e100560.44","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.vaccine.2013.08.061","article-title":"Colonisation endpoints in Streptococcus pneumoniae vaccine trials","volume":"32","author":"Auranen","year":"2013","journal-title":"Vaccine (Auckl)"},{"key":"2025093002151310000_15.9.e100560.45","doi-asserted-by":"crossref","unstructured":"Halloran M , Longini I , Struchiner C . Design and analysis of vaccine studies. Springer, 2010.","DOI":"10.1007\/978-0-387-68636-3"},{"key":"2025093002151310000_15.9.e100560.46","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1186\/s12879-020-05083-7","article-title":"Measuring vaccine effectiveness against persistent HPV infections: a comparison of different statistical approaches","volume":"20","author":"Donken","year":"2020","journal-title":"BMC Infect Dis"},{"key":"2025093002151310000_15.9.e100560.47","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.1016\/j.vaccine.2015.01.072","article-title":"Comparing vaccines: a systematic review of the use of the non-inferiority margin in vaccine trials","volume":"33","author":"Donken","year":"2015","journal-title":"Vaccine (Auckl)"},{"key":"2025093002151310000_15.9.e100560.48","doi-asserted-by":"crossref","unstructured":"Middeldorp M , Duijster JW , Knol MJ , et al . The indirect effect of the bivalent human papillomavirus vaccination program: an observational cohort study. Presented at Eurogin conference, Stockholm; 2024","DOI":"10.1101\/2025.02.28.25323074"},{"key":"2025093002151310000_15.9.e100560.49","unstructured":"Quebec Immunization Committee, Sauvageau Chantal . Human papillomavirus vaccination schedule for people aged 20 and under in Quebec. 2024. Available: https:\/\/www.inspq.qc.ca\/publications\/3495 [Accessed 04 Oct 2024]."},{"key":"2025093002151310000_15.9.e100560.50","unstructured":"Centers for Disease Control and Prevention (CDC) . Human papillomavirus (HPV), vaccination & cancer prevention. 2021. Available: https:\/\/www.cdc.gov\/vaccines\/vpd\/hpv [Accessed 18 May 2024]."},{"key":"2025093002151310000_15.9.e100560.51","unstructured":"U.S. Food and Drug Administration (FDA) . Human papillomavirus vaccine, 2018. Available: https:\/\/www.fda.gov\/vaccines-blood-biologics\/human-papillomavirus-vaccine [Accessed 18 May 2024]."}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2025-100560","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T09:16:13Z","timestamp":1759223773000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2025-100560"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":51,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2025,9,30]]},"published-print":{"date-parts":[[2025,9]]}},"alternative-id":["10.1136\/bmjopen-2025-100560"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2025-100560","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"type":"print","value":"2044-6055"},{"type":"electronic","value":"2044-6055"}],"subject":[],"published":{"date-parts":[[2025,9]]}}}